血清 CCL2 作为前列腺癌预后生物标志物的效用：一项长期随访研究。

Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study.

机构信息

Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.

出版信息

Jpn J Clin Oncol. 2022 Nov 3;52(11):1337-1344. doi: 10.1093/jjco/hyac102.

DOI:10.1093/jjco/hyac102

PMID:35726158

Abstract

OBJECTIVE

Prostate-specific antigen is considered the most useful biomarker for prostate cancer, but not in all cases. In a previous study, we have shown that a risk classification combining prostate-specific antigen ≥100 ng/mL and chemokine (CC motif) ligand 2 ≥ 320 pg/mL can predict survivals. We investigated the long-term usefulness of serum chemokine (CC motif) ligand 2 as a complementary biomarker to prostate-specific antigen and developed a novel risk classification system.

METHODS

Serum samples were collected from 379 patients who underwent prostate biopsy at Kanazawa University Hospital between 2007 and 2013, and 255 patients with histologically diagnosed prostate cancer were included in this study. We retrospectively examined the efficacy of serum chemokine (CC motif) ligand 2 as a prognostic biomarker.

RESULTS

Patients with chemokine (CC motif) ligand 2 ≥ 320 pg/mL exhibited a significantly shorter overall survival, prostate cancer-specific survival and castration-resistant prostate cancer-free survival than those with chemokine (CC motif) ligand 2 < 320 pg/mL. Multivariate analysis was performed to determine whether chemokine (CC motif) ligand 2 was a useful prognostic factor. Independent significant predictors of worse overall survival were prostate-specific antigen ≥ 100 ng/mL, Gleason score ≥ 8 and chemokine (CC motif) ligand 2 ≥ 320 pg/dL. Prognostic predictors of prostate cancer-specific survival or cancer-free survival in multivariate analysis were prostate-specific antigen ≥ 100 ng/mL and Gleason score ≥ 8. A novel risk classification system was created to predict overall survival in patients based on the number of risk factors present (chemokine (CC motif) ligand 2 ≥ 320 pg/mL, prostate-specific antigen ≥ 100 ng/mL, Gleason score ≥ 8). Scores 2 or 3, 1 and 0 indicated Poor, Intermediate and Good risk groups, respectively.

CONCLUSIONS

This study demonstrated the utility of serum chemokine (CC motif) ligand 2 level as a predictive biomarker of long-term overall survival in prostate cancer. A novel risk classification system that predicts long-term overall survival based on the combined indications of chemokine (CC motif) ligand 2 level, prostate-specific antigen level and Gleason score may be a useful prognostic tool for prostate cancer.

摘要

目的

前列腺特异性抗原（PSA）被认为是前列腺癌最有用的生物标志物，但并非在所有情况下均如此。在之前的研究中，我们已经证明，一种将 PSA≥100ng/mL 和趋化因子（CC 基序）配体 2≥320pg/mL 相结合的风险分类方法可以预测患者的生存情况。我们研究了血清趋化因子（CC 基序）配体 2 作为 PSA 互补生物标志物的长期有效性，并开发了一种新的风险分类系统。

方法

收集了 2007 年至 2013 年期间在金泽大学医院接受前列腺活检的 379 名患者的血清样本，其中 255 名患者被诊断为组织学前列腺癌。我们回顾性地检测了血清趋化因子（CC 基序）配体 2 作为预后生物标志物的疗效。

结果

与趋化因子（CC 基序）配体 2<320pg/mL 的患者相比，趋化因子（CC 基序）配体 2≥320pg/mL 的患者总生存、前列腺癌特异性生存和去势抵抗性前列腺癌无进展生存时间明显缩短。多变量分析确定了趋化因子（CC 基序）配体 2 是否为有用的预后因素。总生存的独立显著预测因素为 PSA≥100ng/mL、Gleason 评分≥8 和趋化因子（CC 基序）配体 2≥320pg/dL。多变量分析中前列腺癌特异性生存或无癌生存的预后预测因素为 PSA≥100ng/mL 和 Gleason 评分≥8。基于存在的风险因素数量（趋化因子（CC 基序）配体 2≥320pg/mL、PSA≥100ng/mL、Gleason 评分≥8），创建了一种新的风险分类系统来预测患者的总体生存情况。评分 2 或 3、1 和 0 分别表示预后差、预后中等和预后良好的风险组。